Faecal secretogranin and chromogranin levels persist over time and are unrelated to disease history and outcome in patients with ulcerative colitis

References

• Al-Shoumer, K. A., & Vasanthy, B. A. (2009). Serum chromogranin A concentration in hyperthyroidism before and after medical treatment. The Journal of Clinical Endocrinology and Metabolism, 94(7), 2321–2324. doi:10.1210/jc.2008-2231
   PubMed Web of Science ®Google Scholar
• Bartolomucci, A., Possenti, R., Mahata, S. K., Fischer-Colbrie, R., Loh, Y. P., & Salton, S. R. J. (2011). The extended granin family: Structure, function, and biomedical implications. Endocrine Reviews, 32(6), 755–797. doi:10.1210/er.2010-0027
   PubMed Web of Science ®Google Scholar
• Baudin, E., Bidart, J. M., Bachelot, A., Ducreux, M., Elias, D., Ruffié, P., & Schlumberger, M. (2001). Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Annals of Oncology, 12(Suppl 2), S79–S82.
   PubMed Web of Science ®Google Scholar
• Bonaz, B. L., & Bernstein, C. N. (2013). Brain-gut interactions in inflammatory bowel disease. Gastroenterology, 144(1), 36–49. doi:10.1053/j.gastro.2012.10.003
   PubMed Web of Science ®Google Scholar
• Ceconi, C., Ferrari, R., Bachetti, T., Opasich, C., Volterrani, M., Colombo, B., … Corti, A. (2002). Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. European Heart Journal, 23(12), 967–974. doi:10.1053/euhj.2001.2977
   PubMed Web of Science ®Google Scholar
• Di Comite, G., Rossi, C. M., Marinosci, A., Lolmede, K., Baldissera, E., Aiello, P., … Manfredi, A. A. (2009). Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. Journal of Leukocyte Biology, 85(1), 81–87. doi:10.1189/jlb.0608358
   PubMed Web of Science ®Google Scholar
• Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., … Van Assche, G. (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. Journal of Crohn’s & Colitis, 6(10), 991–1030. doi:10.1016/j.crohns.2012.09.002
   PubMed Web of Science ®Google Scholar
• Egger, M., Beer, A. G., Theurl, M., Schgoer, W., Hotter, B., Tatarczyk, T., … Kirchmair, R. (2008). Monocyte migration: A novel effect and signaling pathways of catestatin. European Journal of Pharmacology, 598(1–3), 104–111. doi:10.1016/j.ejphar.2008.09.016
   PubMed Web of Science ®Google Scholar
• Eissa, N., Hussein, H., Kermarrec, L., Ali, A. Y., Marshall, A., Metz-Boutigue, M.-H., … Ghia, J.-E. (2018). Chromogranin-A regulates macrophage function and the apoptotic pathway in murine DSS colitis. Journal of Molecular Medicine (Berlin, Germany), 96(2), 183–198. doi:10.1007/s00109-017-1613-6
   PubMed Web of Science ®Google Scholar
• Gross, K. J., & Pothoulakis, C. (2007). Role of neuropeptides in inflammatory bowel disease. Inflammatory Bowel Diseases, 13(7), 918–932. doi:10.1002/ibd.20129
   PubMed Web of Science ®Google Scholar
• Hsiao, R. J., Mezger, M. S., & O’Connor, D. T. (1990). Chromogranin A in uremia: Progressive retention of immunoreactive fragments. Kidney International, 37(3), 955–964.
   PubMed Web of Science ®Google Scholar
• Karger, S., Wiesner, T., Kersting, A., Braun, M., Ebert, T., Wurst, U., … Fasshauer, M. (2014). Increased chromogranin a and carcinoid syndrome-like symptoms in a patient treated with duloxetine. Endocrine Practice, 20(11), e215–e218. doi:10.4158/EP14162.CR
   PubMed Web of Science ®Google Scholar
• Lasson, A., Öhman, L., Stotzer, P.-O., Isaksson, S., Überbacher, O., Ung, K.-A., & Strid, H. (2015). Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterology Journal, 3(1), 72–79. doi:10.1177/2050640614560785
   PubMed Web of Science ®Google Scholar
• Ohman, L., Stridsberg, M., Isaksson, S., Jerlstad, P., & Simrén, M. (2012). Altered levels of fecal chromogranins and secretogranins in IBS: Relevance for pathophysiology and symptoms? The American Journal of Gastroenterology, 107(3), 440–447. doi:10.1038/ajg.2011.458
   PubMed Web of Science ®Google Scholar
• Ottesen, A. H., Louch, W. E., Carlson, C. R., Landsverk, O. J. B., Kurola, J., Johansen, R. F., … Røsjø, H. (2015). Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. Journal of the American College of Cardiology, 65(4), 339–351. doi:10.1016/j.jacc.2014.10.065
   PubMed Web of Science ®Google Scholar
• Pregun, I., Herszényi, L., Juhász, M., Miheller, P., Hritz, I., Patócs, A., … Tulassay, Z. (2011). Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion, 84(1), 22–28. doi:10.1159/000321535
   PubMed Web of Science ®Google Scholar
• Reinisch, N., Kirchmair, R., Kähler, C. M., Hogue-Angeletti, R., Fischer-Colbrie, R., Winkler, H., & Wiedermann, C. J. (1993). Attraction of human monocytes by the neuropeptide secretoneurin. FEBS Letters, 334(1), 41–44.
   PubMed Web of Science ®Google Scholar
• Rossi, R. E., Garcia-Hernandez, J., Meyer, T., Thirlwell, C., Watkins, J., Martin, N. G., … Toumpanakis, C. (2015). Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Annals of Translational Medicine, 3(9), 118.
   PubMed Web of Science ®Google Scholar
• Rozansky, D. J., Wu, H., Tang, K., Parmer, R. J., & O’Connor, D. T. (1994). Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. The Journal of Clinical Investigation, 94(6), 2357–2368. doi:10.1172/JCI117601
   PubMed Web of Science ®Google Scholar
• Schonhoff, S. E., Giel-Moloney, M., & Leiter, A. B. (2004). Minireview: Development and differentiation of gut endocrine cells. Endocrinology, 145(6), 2639–2644. doi:10.1210/en.2004-0051
   PubMed Web of Science ®Google Scholar
• Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. The New England Journal of Medicine, 317(26), 1625–1629. doi:10.1056/NEJM198712243172603
   PubMed Web of Science ®Google Scholar
• Sciola, V., Massironi, S., Conte, D., Caprioli, F., Ferrero, S., Ciafardini, C., … Piodi, L. (2009). Plasma chromogranin a in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 15(6), 867–871. doi:10.1002/ibd.20851
   PubMed Web of Science ®Google Scholar
• Shooshtarizadeh, P., Zhang, D., Chich, J.-F., Gasnier, C., Schneider, F., Haïkel, Y., … Metz-Boutigue, M.-H. (2010). The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity. Regulatory Peptides, 165(1), 102–110. doi:10.1016/j.regpep.2009.11.014
   PubMedGoogle Scholar
• Strid, H., Simrén, M., Lasson, A., Isaksson, S., Stridsberg, M., & Öhman, L. (2013). Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. Journal of Crohn’s & Colitis, 7(12), e615–e622. doi:10.1016/j.crohns.2013.04.019
   PubMedGoogle Scholar
• Stridsberg, M., Eriksson, B., & Janson, E. T. (2008). Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regulatory Peptides, 148(1–3), 95–98. doi:10.1016/j.regpep.2008.03.007
   PubMedGoogle Scholar
• Villanacci, V., Bassotti, G., Nascimbeni, R., Antonelli, E., Cadei, M., Fisogni, S., … Geboes, K. (2008). Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterology and Motility, 20(9), 1009–1016. doi:10.1111/j.1365-2982.2008.01146.x
   PubMed Web of Science ®Google Scholar
• Wagner, M., Stridsberg, M., Peterson, C. G., Sangfelt, P., Lampinen, M., & Carlson, M. (2013). Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis. Inflammation, 36(4), 855–861. doi:10.1007/s10753-013-9612-4
   PubMed Web of Science ®Google Scholar
• Welin, S., Stridsberg, M., Cunningham, J., Granberg, D., Skogseid, B., Oberg, K., … Janson, E. T. (2009). Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology, 89(3), 302–307. doi:10.1159/000179900
   PubMed Web of Science ®Google Scholar
• Zissimopoulos, A., Vradelis, S., Konialis, M., Chadolias, D., Bampali, A., Constantinidis, T., … Kouklakis, G. (2014). Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: A prospective observational study. Scandinavian Journal of Gastroenterology, 49(8), 942–949. doi:10.3109/00365521.2014.920910
   PubMed Web of Science ®Google Scholar